Kollins John A 4
4 · Satsuma Pharmaceuticals, Inc. · Filed Jun 7, 2022
Insider Transaction Report
Form 4
Kollins John A
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2022-06-03+505,000→ 505,000 totalExercise: $3.46Exp: 2032-06-02→ Common Stock (505,000 underlying)
Footnotes (1)
- [F1]Twenty Five Percent (25%) of the shares subject to the option vest one year measured from June 3, 2022 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.